Insulet Corporation $PODD Shares Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its stake in Insulet Corporation (NASDAQ:PODD) by 41.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,030 shares of the medical instruments supplier’s stock after buying an additional 3,514 shares during the period. Illinois Municipal Retirement Fund’s holdings in Insulet were worth $3,780,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PODD. Vanguard Group Inc. increased its stake in Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after purchasing an additional 178,976 shares in the last quarter. American Century Companies Inc. grew its holdings in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Groupama Asset Managment increased its position in shares of Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after buying an additional 3,759 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Insulet by 4.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock worth $177,096,000 after buying an additional 27,408 shares during the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Insulet by 23.4% in the 1st quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier’s stock worth $166,198,000 after buying an additional 120,197 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PODD shares. Zacks Research upgraded shares of Insulet from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. UBS Group lifted their price objective on Insulet from $320.00 to $355.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. BTIG Research reissued a “buy” rating and set a $370.00 price target on shares of Insulet in a research report on Thursday, November 6th. Finally, Oppenheimer boosted their price target on Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $374.10.

Insiders Place Their Bets

In other news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Insulet Stock Up 3.2%

PODD opened at $336.84 on Thursday. Insulet Corporation has a 12 month low of $230.05 and a 12 month high of $353.50. The business has a 50-day moving average of $324.17 and a two-hundred day moving average of $311.37. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The stock has a market capitalization of $23.70 billion, a price-to-earnings ratio of 102.38, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.